| Literature DB >> 24147897 |
Shilong Fu1, Lihua Dong, Wei Sun, Yi Xu, Li Gao, Yi Miao.
Abstract
The tumor microenvironment plays an important role in the progression of cancer. This study focused on carcinoma-associated fibroblasts (CAFs) and stromal-epithelial interaction between CAFs and epithelial ovarian carcinoma (EOC) cells. We isolated and established primary cultures of CAFs and co-cultured CAFs and EOC cells in vitro. The co-culture conditioned medium (CC-CM) was harvested and its influence on EOC cells was examined. Cytokine, chemokine, and growth factor levels were screened using a biotin label-based human antibody array system. We found that the stromal-epithelial crosstalk provided a suitable microenvironment for the progression of ovarian cancer cells in vitro.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24147897 PMCID: PMC3887600 DOI: 10.3109/07357907.2013.849723
Source DB: PubMed Journal: Cancer Invest ISSN: 0735-7907 Impact factor: 2.176
Figure 1 Typical morphology and characterization of CAFs harvested from human EOC tissues. Typical CAF morphology: (A) spindle-shaped, (B) intermediate, and (C) flattened. Positive immunohistochemical staining for (D) α-SMA, (E) vimentin, and (F) FSP1, original magnification ×200.
Figure 2 Effect of CC-CM on the proliferation, migration, and invasion of EOC cell lines. A: Proliferation of OVCAR-3 cells cultured in CC-CM or control medium. B: Proliferation of SKOV-3 cells cultured in CC-CM or control medium. C: Migration of OVCAR-3 and SKOV-3 cells cultured in CC-CM or control medium. D: Invasion of OVCAR-3 and SKOV-3 cells cultured in CC-CM or control medium. *p < .05.
Figure 3 Effect of CC-CM on serum deprivation–induced apoptosis of EOC cell lines. A and B: Flow cytometric analyses and quantification of serum deprivation–induced apoptosis in OVCAR-3 cells cultured in CC-CM or control medium. C and D: Flow cytometric analyses and quantification of serum deprivation–induced apoptosis in SKOV-3 cells cultured in CC-CM or control medium. *p < .05.
Figure 4 The interaction of CAFs with OVCAR-3 cells leads to increased levels of various cytokines (representative results, not of all 507 cytokines). The data are expressed as the fold induction ± s.d. of triplicates. There were significant expression of some cytokines, while the expression of large number other cytokines remained unchanged. Red column, OVCAR-3 cells only; green column, CAFs only; blue column, CAF+OVCAR-3 cells.
Significantly Expressed* Cytokines in CAF and OVCAR-3 Cell CC-CM as Compared to OVCAR-3 cell CM
| Symbol | Full Name | Length | NCBI Ref | Gene ID | Fold-Change |
|---|---|---|---|---|---|
|
| |||||
| TNFSF14 | Tumor necrosis factor superfamily, 14 | 204 aa | NP_742011.2 | 8,740 | 3.4 ± 0.8 |
| PDGF-AB | Platelet-derived growth factor alpha, beta | 196 aa | NP_148983.1 | 5,154 | 3.3 ± 0.8 |
| IGFBP-3 | Insulin-like growth factor binding protein 3 | 291 aa | NP_000589.2 | 3,486 | 3.1 ± 0.9 |
| TGF-beta 1 | Transforming growth factor, beta 1 | 390 aa | NP_000651.3 | 7,040 | 2.8 ± 1.1 |
| BMP-3 | Bone morphogenetic protein 3 | 472 aa | NP_001192.2 | 651 | 2.7 ± 1.3 |
| BMP-15 | Bone morphogenetic protein 15 | 392 aa | NP_005439.2 | 9,210 | 2.7 ± 1.1 |
| Pref-1 | Delta-like 1 homolog (Drosophila) | 383 aa | NP_003827.3 | 8,788 | 2.6 ± 0.8 |
| TSG-6 | Tumor necrosis factor, alpha-induced protein 6 | 277 aa | NP_009046.2 | 7,130 | 2.5 ± 0.4 |
| IGF-1 | Insulin-like growth factor 1 | 153 aa | NP_000609.1 | 3,479 | 2.5 ± 1.3 |
| FGF-BP | Fibroblast growth factor binding protein 1 | 234 aa | NP_005121.1 | 9,982 | 2.4 ± 0.8 |
| HGF | Hepatocyte growth factor (hepapoietin A) | 723 aa | NP_001010932.1 | 3,082 | 2.0 ± 0.6 |
| FGF-20 | Fibroblast growth factor 20 | 211 aa | NP_062825.1 | 26,281 | −2.1 ± 1.2 |
| TNFSF10 | Tumor necrosis factor super family 10 | 101 aa | NP_001177871.1 | 8,743 | −2.2 ± 1.4 |
| FGF-4 | Fibroblast growth factor 4 | 206 aa | NP_001998.1 | 2,249 | −2.3 ± 0.1 |
| FGF-8 | Fibroblast growth factor 8 | 140 aa | NP_001193318.1 | 2,253 | −2.4 ± 1.3 |
| EGF | Epidermal growth factor | 1207 aa | NP_001954.2 | 1,950 | −2.6 ± 0.8 |
|
| |||||
| MMP-20 | Matrix metallopeptidase 20 | 483 aa | NP_004762.2 | 9,313 | 3.2 ± 1.0 |
| MMP-10 | Matrix metallopeptidase 10 | 476 aa | NP_002416.1 | 4,319 | 2.7 ± 0.3 |
| TIMP-4 | TIMP metallopeptidase inhibitor 4 | 224 aa | NP_003247.1 | 7,079 | 2.5 ± 1.1 |
| MMP-13 | Matrix metallopeptidase 13 | 471 aa | NP_002418.1 | 4,322 | 2.4 ± 0.5 |
| MMP-11 | Matrix metallopeptidase 11 | 488 aa | NP_005931.2 | 4,320 | 2.3 ± 0.8 |
| S100A10 | S100 calcium binding protein A10 | 97 aa | NP_002957.1 | 6,281 | 2.2 ± 0.2 |
| ICAM-3 | Intercellular adhesion molecule 3 | 547 aa | NP_002153.2 | 3,385 | 2.2 ± 0.5 |
| TFPI | Tissue factor pathway inhibitor | 304 aa | NP_006278.1 | 7,035 | 2.1 ± 0.4 |
| MMP-25 | Matrix metallopeptidase 25 | 562 aa | NP_071913.1 | 64,386 | 2.1 ± 0.3 |
| CTGF | Connective tissue growth factor | 349 aa | NP_001892.1 | 1,490 | 2.0 ± 0.5 |
| MMP-1 | Matrix metallopeptidase 1 | 403 aa | NP_001139410.1 | 4,312 | 2.0 ± 0.7 |
|
| |||||
| IL-1A | Interleukin 1, alpha | 271 aa | NP_000566.3 | 3,552 | 3.4 ± 0.4 |
| IL-26 | Interleukin 26 | 171 aa | NP_060872.1 | 55,801 | 2.9 ± 0.6 |
| IL-17C | Interleukin 17C | 197 aa | NP_037410.1 | 27,189 | 2.7 ± 0.3 |
| IL-19 | Interleukin 19 | 215 aa | NP_715639.1 | 29,949 | 2.7 ± 0.8 |
| IL-28A | Interleukin 28A (interferon, lambda 2) | 200 aa | NP_742150.1 | 282,616 | 2.5 ± 0.2 |
| Eotaxin | Chemokine (C-C motif) ligand 11 | 97 aa | NP_002977.1 | 6,356 | 2.5 ± 0.6 |
| IL-22 | Interleukin 22 | 179 aa | NP_065386.1 | 50,616 | 2.4 ± 0.6 |
| IL-12 A | Interleukin 12 A | 253aa | NP_000873.2 | 3,592 | 2.4 ± 0.8 |
| IL-31 | Interleukin 31 | 164 aa | NP_001014358.1 | 386,653 | 2.3 ± 0.4 |
| IL-27 | Interleukin 27 | 243 aa | NP_663634.2 | 246,778 | 2.3 ± 0.6 |
| CXCL12 | Chemokine (C-X-C motif) ligand 12 | 273 aa | NP_071342.2 | 58,191 | 2.3 ± 0.5 |
| IL-15 | Interleukin 15 | 135 aa | NP_751915.1 | 3,600 | 2.2 ± 0.3 |
| IL-4 | Interleukin 4 | 153 aa | NP_000580.1 | 3,565 | 2.2 ± 0.4 |
| PARC / CCL18 | Chemokine (C-C motif) ligand 18 | 89 aa | NP_002979.1 | 6,362 | −2.2 ± 0.8 |
| IL-13 | Interleukin 13 | 146 aa | NP_002179.2 | 3,596 | −2.3 ± 0.6 |
| RANTES | Chemokine (C-C motif) ligand 5 | 91 aa | NP_002976.2 | 6,352 | −2.4 ± 0.4 |
| GCP-2 / CXCL6 | Chemokine (C-X-C motif) ligand 6 | 114 aa | NP_002984.1 | 6,372 | −243 ± 0.5 |
| IL-10 | Interleukin 10 | 178 aa | NP_000563.1 | 3,586 | −2.4 ± 0.8 |
| ENA-78 | Chemokine (C-X-C motif) ligand 5 | 114 aa | NP_002985.1 | 6,374 | −2.5 ± 0.5 |
|
| |||||
| VEGF-B | Vascular endothelial growth factor B | 207 aa | NP_003368.1 | 7,423 | 3.3 ± 0.6 |
| Angiopoietin-4 | Angiopoietin 4 | 503aa | NP_057069.1 | 51,378 | 3.0 ± 0.1 |
| Endoglin / CD105 | Endoglin | 658 aa | NP_001108225.1 | 2,022 | 2.4 ± 0.4 |
| VE-Cadherin | Cadherin 5, type 2 (vascular endothelium) | 784 aa | NP_001786.2 | 1,003 | 2.3 ± 0.2 |
| VEGF-C | Vascular endothelial growth factor C | 419 aa | NP_005420.1 | 7,424 | 2.3 ± 0.6 |
| TMEFF2 | Transmembrane protein with EGF-like 2 | 374 aa | NP_057276.2 | 23,671 | 2.3 ± 0.2 |
| EDG-1 | Hexamethylene bis-acetamide inducible 1 | 359 aa | NP_006451.1 | 10,614 | 2.2 ± 0.1 |
| Angiopoietin-1 | Angiopoietin 1 | 497 aa | NP_001186788.1 | 284 | 2.1 ± 0.5 |
| VEGF | Vascular endothelial growth factor A | 412 aa | NP_001020537.2 | 7,422 | 2.0 ± 0.8 |
| Angiopoietin-like 4 | Angiopoietin-like 4 | 406 aa | NP_647475.1 | 51,129 | −2.1 ± 0.5 |
| Tie-1 | Tyrosine kinase with EGF-like domains 1 | 1138 aa | NP_005415.1 | 7,075 | −2.4 ± 0.3 |
The CM was harvested from CAFs, OVCAR-3 cells, or CAF and OVCAR-3 cell co-cultures. The levels of various factors in the cell-free culture supernatants were measured with the RayBio® Biotin Label-based Human Antibody Array system and normalized to the levels observed in the medium of OVCAR-3 cells cultured alone.
We defined an arbitrary cutoff signal ratio of ≥2.0- or ≤2.0-fold changes as significant expression. aa, amino acid; NCBI Ref, National Center of Biotechnology Information reference sequence: LOCUS.